Friday November 27 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

«Amylin Pharmaceuticals Incorporated

Below is an extended Amylin Pharmaceuticals Incorporated patents listing. Click here to return to the Amylin Pharmaceuticals Incorporated main Biocorporate entry.

Amylin Pharmaceuticals Incorporated Patents :

US Patent No.Title
6579851 Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
6936584 Mixed amylin activity compounds
6956026 Use of exendins for the reduction of food intake
6982248 Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
6989366 Exendins, exendin agonists, and methods for their use
6998387 Human appetite control by glucagon-like peptide receptor binding compounds
7056887 Treatment of acute coronary syndrome with GLP-1
7101853 Method for treating or preventing gastritis using amylin or amylin agonists
7105489 Methods and compositions for treating polycystic ovary syndrome
7105490 Methods and compositions for treating polycystic ovary syndrome
7115569 Exendins, exendin agonists, and methods for their use
6924264 Modified exendins and exendin agonists
6902744 Exendin agonist formulations and methods of administration thereof
6894024 Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
6602694 Uncoupling protein 4 (UCP-4)
6608029 Methods for regulating gastrointestinal motility
6610824 Amylin agonist peptides and uses therefor
6703359 Inotropic and diuretic effects of exendin and GLP-1
6706689 Treatment of acute coronary syndrome with GLP-1
6723530 Polynucleotides encoding proexendin, and methods and uses thereof
6852690 Method and composition for enhanced parenteral nutrition
6858576 Methods for regulating gastrointestinal motility
6872700 Methods for glucagon suppression
6884579 GLP-1 as a diagnostic test to determine .beta.-cell function and the presence of the condition of IGT and type-II diabetes
7118737 Polymer-modified synthetic proteins
7129327 Polypeptide and protein derivatives and process for their preparation
7407934 Methods for regulating postprandial blood glucose
7419952 Use of exendins and agonists thereof to treat diabetes
7442680 Inotropic and diuretic effects of GLP-1 and GLP-1 agonists
7452858 Treatment of gestational diabetes
7482425 Compositions for lipid matrix-assisted chemical ligation
7521423 Exendin pharmaceutical compositions
7538182 Polypeptide and protein derivatives and process for their preparation
7563871 Polymer-based sustained release device
7566697 Carboxy protection strategies for acidic C-terminal amino acids in chemical ligation of oligopeptides
7569540 Method for enhanced parenteral nutrition
7407932 Methods for glucagon suppression using modified exendins
7399744 Methods for affecting body composition
7399489 Exendin analog formulations
7138375 Use of exendins and agonists thereof for lowering plasma lipid
7153825 Methods for glucagon suppression using modified exendins
7157555 Exendin agonist compounds
7220721 Exendin agonist peptides
7223725 Exendin agonist compounds
7259136 Compositions and methods for treating peripheral vascular disease
7265087 Exendin improves .beta.-cell response in subjects with impaired glucose tolerance
7271238 Amylin agonist peptides and uses therefor
7297761 Pharmaceutical compositions containing exendins
7312196 Formulations for amylin agonist peptides
7608692 Exendins and exendin agonists modified with albumin

«Amylin Pharmaceuticals Incorporated

This page contained an extended Amylin Pharmaceuticals Incorporated patents listing. Click here to return to the Amylin Pharmaceuticals Incorporated main Biocorporate entry.

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.